Soligenix extends patent protection for its filovirus vaccine platform to the united kingdom and south africa

Includes thermostabilized ebola vaccines marvax™ and suvax™ includes nanoemulsion adjuvant compatible with lyophilization princeton, n.j. , april 25, 2024 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received notice of intent to grant additional patents based on its patent application titled "compositions and methods of manufacturing trivalent filovirus vaccines" in the united kingdom and south africa, with other international jurisdictions pending.
SNGX Ratings Summary
SNGX Quant Ranking